Receptor for AGEs (RAGE) blockade may exert its renoprotective effects in patients with diabetic nephropathy via induction of the angiotensin II type 2 (AT2) receptor.
about
High Mobility Group Box-1: A Missing Link between Diabetes and Its ComplicationsMicrovascular vasodilator properties of the angiotensin II type 2 receptor in a mouse model of type 1 diabetes.Vascular remodeling and arterial calcification are directly mediated by S100A12 (EN-RAGE) in chronic kidney disease.Clearance kinetics and matrix binding partners of the receptor for advanced glycation end products.Alagebrium reduces glomerular fibrogenesis and inflammation beyond preventing RAGE activation in diabetic apolipoprotein E knockout miceThe Mouse-Specific Splice Variant mRAGE_v4 Encodes a Membrane-Bound RAGE That Is Resistant to Shedding and Does Not Contribute to the Production of Soluble RAGE.AGE restriction in diabetes mellitus: a paradigm shift.Renal Protective Role of Xiexin Decoction with Multiple Active Ingredients Involves Inhibition of Inflammation through Downregulation of the Nuclear Factor-κB Pathway in Diabetic Rats.Targeting of receptor for advanced glycation end products suppresses cyst growth in polycystic kidney disease.RAGE biology, atherosclerosis and diabetes.Pathophysiology of the diabetic kidney.The pathobiology of diabetic vascular complications--cardiovascular and kidney disease.Angiotensin II type II receptor deficiency accelerates the development of nephropathy in type I diabetes via oxidative stress and ACE2.Podocytes of AT2 receptor knockout mice are protected from angiotensin II-mediated RAGE induction.Diminazene aceturate prevents nephropathy by increasing glomerular ACE2 and AT2 receptor expression in a rat model of type1 diabetes.Protective effect of L-glutamine against diabetes-induced nephropathy in experimental animal: Role of KIM-1, NGAL, TGF-β1, and collagen-1.D-ribose induces nephropathy through RAGE-dependent NF-κB inflammation
P2860
Q28066302-16A3276F-113C-4009-A2F9-E034A076CCFFQ30843430-17D0CA77-96AD-48C1-A4DD-741AFC35F813Q34724983-9AE56FA6-201E-471E-AE7D-5902A5D30E43Q35124150-5C406E2E-87F6-4E5E-839D-B0348C89A315Q36109288-9BFA4EFB-F2B4-4400-8D59-BEFA90ACFFADQ36139994-6E5F06D8-1FDE-4A02-B66E-3A45148D3B7BQ37003623-3A72AC6B-B8E2-4ED5-888B-BE0EEFD7E440Q37019804-9075AAE4-2261-4AC6-9516-70D3FC133A04Q37691594-789557DD-71B1-475C-9586-A8AA43AFD571Q37860348-6A369F7C-16AB-4D9B-AB8B-60A86FD34508Q38111707-C31410F2-767C-42BF-9FB5-C0AA5AD59533Q38200957-3F28A35A-7E02-4131-A5BA-1D094A9FAF5CQ38895396-C1BBD4EB-EF90-4CA8-B1F2-397963366128Q45713726-5C32EC2E-F432-42EE-95FC-D2EA49D9938CQ48157747-C5E0BF38-D087-4AEE-9183-89C65DB7D097Q51378901-1EC86D47-D7EE-4F5F-BA28-4773F86D6571Q58784334-6F210CAB-6D9D-4F1B-9C4B-72D9956A5432
P2860
Receptor for AGEs (RAGE) blockade may exert its renoprotective effects in patients with diabetic nephropathy via induction of the angiotensin II type 2 (AT2) receptor.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 15 July 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Receptor for AGEs (RAGE) block ...... nsin II type 2 (AT2) receptor.
@en
Receptor for AGEs
@nl
type
label
Receptor for AGEs (RAGE) block ...... nsin II type 2 (AT2) receptor.
@en
Receptor for AGEs
@nl
prefLabel
Receptor for AGEs (RAGE) block ...... nsin II type 2 (AT2) receptor.
@en
Receptor for AGEs
@nl
P2093
P2860
P1433
P1476
Receptor for AGEs (RAGE) block ...... ensin II type 2 (AT2) receptor
@en
P2093
A Bierhaus
A L Morley
H Yamamoto
K C Sourris
M E Cooper
M T Coughlan
P P Nawroth
S A Penfold
P2860
P2888
P304
P356
10.1007/S00125-010-1837-2
P577
2010-07-15T00:00:00Z